Cyclacel Pharmaceuticals, Inc. (CYCC)

Market Cap	2.11M
Revenue (ttm)	420,000
Net Income (ttm)	-22.76M
Shares Out	1.32M
EPS (ttm)	-26.75
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,457,774
Open	1.780
Previous Close	2.280
Day's Range	1.410 - 1.987
52-Week Range	1.410 - 13.200
Beta	0.57
Analysts	Buy
Price Target	70.50 (+4,306.25%)
Earnings Date	May 9, 2024

About CYCC

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kina...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1992
• Employees: 12
• Stock Exchange: NASDAQ
• Ticker Symbol: CYCC

Analyst Forecast

According to 3 analysts, the average rating for CYCC stock is "Buy." The 12-month stock price forecast is $70.5, which is an increase of 4,306.25% from the latest price.

Price Target

$70.5

(4,306.25% upside)

Analyst Consensus: Buy